Filgrastim 300 mcg
Si Disponible: Dispensado al Día Siguiente
Envío Gratis
Dentro de México
Requiere Receta Médica
Este Medicamento requiere prescripción médica de su médico, clínica, hospital o terapeuta.
Filgrastim
Marca de Patente: NEUPOGEN
Clase:
Factores estimulantes de colonias
Cómo Suministrado:
-Solución para inyección intravenosa: 0,5 ml, 0,8 ml, 1 ml, 1,6 ml, 300 mcg, 480 mcg
-Solución para inyección subcutánea: 0,5 ml, 0,8 ml, 1 ml, 1,6 ml, 300 mcg, 480 mcg
DESCRIPCIÓN:
Factor estimulante de colonias de granulocitos. Se utiliza para reducir la duración de la neutropenia y la incidencia de infección en pacientes que reciben quimioterapia mielosupresora o quimioterapia mieloablativa seguida de un trasplante de médula ósea; También se utiliza para la movilización de células progenitoras de sangre periférica para leucoféresis, para el tratamiento de la neutropenia crónica grave y para mejorar la supervivencia después de una exposición aguda a la radiación.
Description
FILGRASTIM 300 mcg
Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF)
Therapeutic Class: Immunostimulant / Hematopoietic Growth Factor
Marca: NEUPOGEN
Product Description:
Filgrastim is a recombinant human granulocyte colony-stimulating factor (rhG-CSF) used to stimulate the production and activation of neutrophils. Manufactured using recombinant DNA technology in Escherichia coli, it is structurally similar to endogenous human G-CSF and is widely used to treat or prevent chemotherapy-induced neutropenia, bone marrow suppression, and chronic neutropenic conditions.Available Presentations:
- Strength: 300 mcg (0.3 mg) per vial or prefilled syringe
- Form: Solution for Injection
- Volume: 1 mL (300 mcg/mL)
- Packaging: Single-dose vial or prefilled syringe with safety needle
- Route of Administration: Subcutaneous (SC) or Intravenous (IV)
- Storage: Store between 2°C and 8°C; do not freeze; protect from light
Uses:
- Reduction of neutropenia duration and incidence of febrile neutropenia in patients undergoing myelosuppressive chemotherapy
- Mobilization of peripheral blood progenitor cells (PBPCs) for stem cell transplantation
- Treatment of severe chronic neutropenia (SCN) including congenital, cyclic, or idiopathic types
- Management of HIV/AIDS-related neutropenia and radiation-induced myelosuppression (off-label)
Indications:
- Oncology: Cancer patients receiving cytotoxic chemotherapy
- Transplantation: Bone marrow or hematopoietic stem cell transplant recipients
- Hematology: Patients with congenital or idiopathic neutropenia
- Immunodeficiency: HIV patients with treatment-associated neutropenia
- Emergency Use: Radiation exposure support (government-authorized programs)
Regulatory and Safety Profile:
- ATC Code: L03AA02
- WHO Essential Medicines List: Yes
- Pharmacologic Class: Colony-Stimulating Factor (CSF)
- Contraindications: Hypersensitivity to Filgrastim or E. coli–derived proteins
- Warnings: Risk of splenic rupture, ARDS, and excessive leukocytosis
- Common Adverse Effects: Bone pain, musculoskeletal discomfort, leukocytosis, injection site reactions
For institutional pricing, biosimilar availability, and regulatory documentation, please contact our commercial office at info@panamfarma.com.
